ARS Pharmaceuticals (SPRY) Accumulated Expenses (2020 - 2026)

ARS Pharmaceuticals has reported Accumulated Expenses for 6 years, with the latest figure at $5.8 million in Q1 2026.

• Quarterly Accumulated Expenses changed N/A year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (changed N/A YoY) and the FY2025 annual result came in at $4.6 million, up 146.74% from the prior year.
• Accumulated Expenses rose to $5.8 million in Q1 2026 per SPRY's latest filing, from $4.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.0 million in Q4 2022 and troughed at $404000.0 in Q1 2022.
• A 4-year average of $3.7 million and a median of $2.1 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses sank 93.03% in 2022, then jumped 146.74% in 2025.
• Over 4 years, Accumulated Expenses stood at $12.0 million in 2022, then slumped by 84.54% to $1.9 million in 2024, then soared by 146.74% to $4.6 million in 2025, then rose by 27.66% to $5.8 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $5.8 million, $4.6 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.